A retrospective study to assess the efficacy and safety of JAK inhibitors in the treatment of refractory systemic Juvenile idiopathic Arthritis (sJIA) or Adult and Childhood Onset Still'S Disease
Latest Information Update: 22 Jun 2021
At a glance
- Drugs Baricitinib (Primary) ; Ruxolitinib (Primary) ; Tofacitinib (Primary) ; Anakinra; Methotrexate; Steroids
- Indications Adult-onset Still's disease; Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 22 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism